Subtype
Thyroid Gland Oncocytic Neoplasm
CI-CAN-00004126Explore in graph →
Non-malignant5 active trials1 evidence items
- NCIt
- C46068
Loading cancer entity…
Subtype
CI-CAN-00004126Explore in graph →
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT00381641 | Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2025 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT01811212 |
Data updated 22 days agoSource updated Aug 29, 2025source: clinicaltrials
| completed |
| Phase 2 |
| 25 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 3, 2018 |
| clinicaltrials |